Loading...
OTCM
EPGNF
Market cap3mUSD
Jun 25, Last price  
0.79USD
Name

Epigenomics AG

Chart & Performance

D1W1MN
P/E
—
P/S
9.09
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.17%
Rev. gr., 5y
-26.04%
Revenues
339k
-30.06%
7,931,0009,594,0003,504,0002,567,0002,586,0004,260,0001,787,0001,437,0001,039,0001,588,0001,507,0002,082,0004,201,0001,864,0001,533,0001,125,000842,0006,203,000485,000339,227
Net income
-4m
L-62.88%
10,975,0008,788,000-15,402,000-13,151,000-12,271,000-10,223,000-11,476,000-15,575,000-12,197,000-7,411,000-8,854,000-8,985,000-11,161,000-10,235,000-12,692,000-17,020,000-11,686,000-2,428,000-12,024,000-4,463,523
CFO
-6m
L-52.50%
8,885,0007,501,000-14,308,000-11,244,000-9,800,000-10,629,000-9,479,000-9,111,000-10,884,000-6,505,000-7,221,000-8,127,000-13,283,000-9,576,000-10,351,000-13,506,000-9,571,000-4,152,000-12,024,000-5,710,999

Profile

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
URL
https://www.epigenomics.com/
IPO date
Jul 19, 2004
Employees
36
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
339
-30.06%
485
-92.18%
Cost of revenue
57
10,607
Unusual Expense (Income)
NOPBT
282
(10,122)
NOPBT Margin
83.22%
Operating Taxes
395
(77)
Tax Rate
139.95%
NOPAT
(113)
(10,045)
Net income
(4,464)
-62.88%
(12,024)
395.22%
Dividends
Dividend yield
Proceeds from repurchase of equity
(45)
BB yield
Debt
Debt current
324
Long-term debt
11,889
1,358
Deferred revenue
Other long-term liabilities
8,696
89
Net debt
7,506
(9,141)
Cash flow
Cash from operating activities
(5,711)
(12,024)
CAPEX
(3)
(1,365)
Cash from investing activities
68
(1,700)
Cash from financing activities
(57)
(359)
FCF
1,835
(11,211)
Balance
Cash
2,104
10,036
Long term investments
2,278
787
Excess cash
4,366
10,799
Stockholders' equity
(8,016)
(92,189)
Invested Capital
20,585
103,232
ROIC
ROCE
2.25%
EV
Common stock shares outstanding
853
813
Price
Market cap
EV
EBITDA
845
(9,373)
EV/EBITDA
Interest
130
Interest/NOPBT